LY2623091

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

Chronic Kidney DiseaseHealthy VolunteersPrimary Hypertension

Phase 1

Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance

CompletedNCT01237899

Eli Lilly and CompanyChronic Kidney Disease

Start: 2010-10-31End: 2011-01-31Updated: 2019-06-03

A Study of How the Body Breaks Down and Eliminates LY2623091

CompletedNCT02242981

Eli Lilly and CompanyHealthy Volunteers

Start: 2014-09-30End: 2014-11-30Updated: 2020-06-26

A Study of LY2623091 in Healthy Participants

CompletedNCT02300259

Eli Lilly and CompanyHealthy Volunteers

Start: 2014-11-30End: 2015-04-30Updated: 2020-06-26

Phase 2

A Study of LY2623091 in Male and Females With Chronic Kidney Disease

CompletedNCT01427972

Eli Lilly and CompanyChronic Kidney Disease

Start: 2011-09-30End: 2013-03-31Updated: 2019-09-09

A Study of LY2623091 in Participants With High Blood Pressure

CompletedNCT02194465

Eli Lilly and CompanyPrimary Hypertension

Start: 2014-08-31End: 2015-03-31Updated: 2020-06-26

Related Papers

Physiologically Based Pharmacokinetic Modeling to Understand the Observed Drug–Drug Interaction of LY2623091 with CYP3A Inhibitors Itraconazole and Diltiazem

International Journal of Pharmacokinetics2017-10-133 citations